STUDY OF THE EFFECT OF ETHANOL ALCOHOLS ON YEASTS AND FUNGI ISOLATED FROM THE NAIL

Jumana Sadiq Hassan; Maryam Issa Hameed; Ahmed Ail Hassen; Batool Saleh Chuaied; Zainab Ahmed Sabir; Mona Riyad Kamel

doi:10.61796/jmgcb.v1i6.557

Authors

Jumana Sadiq Hassan
jojosadiq11@gmail.com
Thi_Qar university
Maryam Issa Hameed Thi_Qar university
Ahmed Ail Hassen Thi_Qar university
Batool Saleh Chuaied Thi_Qar university
Zainab Ahmed Sabir Thi_Qar university
Mona Riyad Kamel Thi_Qar university

Vol. 1 No. 6 (2024): Journal of Medical Genetics and Clinical Biology

Articles

June 7, 2024

Downloads

View Article

Abstract
How to Cite
Metrics
References
License

The right to use alcoholic materials excessively, such as 75% ethanol concentration, which is produced locally by several companies, and the use of these materials as sterilizing agents to get rid of certain kinds of viruses or microorganisms, as happened recently due to the Corona virus outbreak, have resulted in an increase in resistance. This study, which involved bleaching a number of yeast species, including Candida albicans, Candida glabrata, Candida krusei, Candida tropicalis, Rhodotorula, and Aspergillus flavus, revealed the emergence of high resistance by those yeasts and fungi to the alcohols used EtOH, surgical, joonandjood, which was caused by certain types of microorganisms, including fungi and yeasts, and the emergence of resistant strains, particularly those that accompanied skin infections or nail injuries. This might be the result of patients' overuse of alcohol and the resistant strains that followed it

Jumana Sadiq Hassan, Maryam Issa Hameed, Ahmed Ail Hassen, Batool Saleh Chuaied, Zainab Ahmed Sabir, & Mona Riyad Kamel. (2024). STUDY OF THE EFFECT OF ETHANOL ALCOHOLS ON YEASTS AND FUNGI ISOLATED FROM THE NAIL. Journal of Medical Genetics and Clinical Biology, 1(6), 40–47. https://doi.org/10.61796/jmgcb.v1i6.557

Download Citation

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004 Aug 1; 39(3):309–17.

Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev. 2004 Apr; 17 (2):255–67. PMID: 15084500

Ramage G, Saville SP, Thomas DP, López-Ribot JL. Candida biofilms: an update. Eukaryot Cell. 2005 Apr; 4(4):633–8. PMID: 15821123

Walraven CJ, Lee SA. Antifungal lock therapy. Antimicrob Agents Chemother. 2013 Jan; 57(1):1–8. doi: 10.1128/AAC.01351-12 PMID: 23070153

Chandra J, McCormick TS, Imamura Y, Mukherjee PK, Ghannoum MA. Interaction of Candida albicans with Adherent Human Peripheral Blood Mononuclear Cells Increases C. albicans Biofilm Formation and Results in Differential Expression of Pro- and Anti-Inflammatory Cytokines. Infect Immun. 2007 May 1; 75(5):2612–20. PMID: 17339351

Katragkou A, Kruhlak MJ, Simitsopoulou M, Chatzimoschou A, Taparkou A, Cotten CJ, et al. Interactions between Human Phagocytes and Candida albicans Biofilms Alone and in Combination with Antifungal Agents. J Infect Dis. 2010 Jun 15; 201(12):1941–9. doi: 10.1086/652783 PMID: 20415537

Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol. 2001 Sep; 183(18):5385–94. PMID: 11514524

Lamfon H. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study. J Antimicrob Chemother. 2004 Jan 16; 53 (2):383–5. PMID: 14729749

Taff HT, Mitchell KF, Edward JA, Andes DR. Mechanisms of Candida biofilm drug resistance. Future Microbiol. 2013 Oct; 8(10):1325–37. doi: 10.2217/fmb.13.101 PMID: 24059922

Nett JE, Crawford K, Marchillo K, Andes DR. Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene. Antimicrob Agents Chemother. 2010 Aug 1; 54(8):3505–8. doi: 10.1128/AAC.00227-10 PMID: 20516280

Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemother. 2010 Feb 1; 65(2):271–4. doi: 10.1093/jac/dkp429 PMID: 19996142

Ramage G, Bachmann S, Patterson TF, Wickes BL, López-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother. 2002Jun; 49(6):973–80. PMID: 12039889

Nett JE, Sanchez H, Cain MT, Andes DR. Genetic basis of Candida biofilm resistance due to drug sequestering matrix glucan. J Infect Dis. 2010 Jul; 202:171–175. doi: 10.1086/651200 PMID: 20497051

Mitchell KF, Zarnowski R, Sanchez H, Edward JA, Reinicke EL, Nett JE, et al. Community participation in biofilm matrix assembly and function. Proc Natl Acad Sci U S A. 2015 Mar 13;

Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun. 2003 Aug; 71(8):4333–40. PMID: 12874310

White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998 Apr; 11(2):382–402. PMID: 9564569

Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003 Feb; 2 (2):114–22. PMID: 12563302

Liu S, Hou Y, Chen X, Gao Y, Li H, Sun S. Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery. Int J Antimicrob Agents. 2014 May; 43(5):395–402. doi: 10.1016/j.ijantimicag.2013. 12.009 PMID: 24503221

Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003 Jun 12; 52(1):1–1. PMID: 12805255

Chavez-Dozal AA, Lown L, Jahng M, Walraven CJ, Lee SA. In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and filamentation. Antimicrob Agents Chemother. 2014 Oct; 58(10):5855–62. doi: 10.1128/AAC.03137-14 PMID: 25049253

Fiori A, Van Dijck P. Potent Synergistic Effect of Doxycycline with Fluconazole against Candida albicans Is Mediated by Interference with Iron Homeostasis. Antimicrob Agents Chemother. 2012 Jul 1; 56 (7):3785–96. doi: 10.1128/AAC.06017-11 PMID: 22564841

Pemmaraju SC, Pruthi PA, Prasad R, Pruthi V. Candida albicans biofilm inhibition by synergistic action of terpenes and fluconazole. Indian J Exp Biol. 2013 Nov; 51(11):1032–7. PMID: 24416942

Chandrasekar PH, Sobel JD. Micafungin: A New Echinocandin. Clin Infect Dis. 2006 Apr 15; 42 (8):1171–8. PMID: 16575738.

Bailey, E. M., D. J. Krakovsky, et al. (1990). "The triazole antifungal agents: a review of itraconazole and fluconazole." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 10(2): 146-153.

Seethalakshmi, I.; Sathishkumar, J.; Muthu, S. and Saritha, V. (2010). Virulence and cytotoxicity of seafood borne Aeromonas hydrophila. Brazil. J. Microbiol., 41: 978-983.

Kuhun, D. M., T. George, et al. (2002). "Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins." Antimicrobial Agents and Chemotherapy 46(6): 1773-1780.

Rippon, J. W. (1988). Medical Mycology. 3rd. W. B. Saunders Co. Philadelphia .U.S.A.

Hajjeh, R. A., A. N. Sofair, et al. (2004). "Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program." Journal of Clinical Microbiology 42(4): 1519-1527.

Sun S, Li Y, Guo Q, Shi C, Yu J & Ma L (2008) In vitro interactions

between tacrolimus and azoles against albicans determined by different methods. Antimicrob Agents Ch 52:409–417.

Cateau E, Rodier M-H, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother. 2008 Apr 1; 62(1):153–5. doi: 10.1093/ jac/dkn160 PMID: 18407917

Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo). 2000 Oct; 53(10):1175–81

Mikamo H. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother. 2000 Sep 1; 46(3):485–7. PMID: 10980180